Soft Tissue Sarcoma

Advanced or Metastatic

Locally Advanced

CCT5031
Phase II
ADP-A2M4
SPEAR T Cells
in Advanced
Synovial
Sarcoma or
Myxoid/Round
Cell
Liposarcoma

Pt: Ganjo
Adaptimmune

CCT5031
Phase II
NY-ESO-1-
Specific (c259)
T Cells +/-
OtherAgents in
HLA-A2+ w/
NY-ESO-1 &/or
LAG3:1a + ST

Pt: Ganjo
Sponsor: GlaxoSmithKline

SARCOMA0038
Phase II
Ipilimumab
+Nivolumab +
Cryotherapy in
Metastatic or
Locally
Advanced Soft
Tissue Sarcoma

Pt: Ganjo
Stanford

SARCOMA0033
Phase II
ADI-PEG 20 w/ Gemcitabine & Docetaxel in Treatment of Soft Tissue Sarcoma

Pt: Bui
Washington University

SARCOMA0043
Phase I
SQ3370 in Advanced Solid Tumors

Pt: Bui
Pending

SARCOMA0045
Phasell
Cytoreductive Surgery+HIPEC w/Gemcitabine +Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma

Pt: Ganjo
Pending

SARCOMA0023
Phase II/III
Selinuxor
(KPT-330) vs Placebo in Advanced Unresectable Dedifferentiated Liposarcoma

Pt: Ganjo
Karyopharm Therapeutics

2nd Line

Dedifferentiated
Liposarcoma and
Osteosarcoma

Dedifferentiated
Liposarcoma only

SARC-024
Phase II
Regorafenib in Refractory Liposarcoma, Osteogenic Sarcoma, & Ewing/Ewing-Like Sarcomas

Pt: Ganjo
SARC

KEY

- - Optional Path

Link

Trial Posting

Extension Study

Immunotherapy

Pending

Open for Enrollment

Observational Study

Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu